|
| |
|
MDMA Ecstasy
(Methylenedioxymethamphetamine)
QuickScreen™ One-Step Rapid
Drug Screen Test (Cassette type)
|
A
Professional, Forensic Diagnostic Test for use in the
Specific Qualitative Detection of MDMA (Ecstasy) in Human Urine at a minimum
sensitivity cut-off level of 500 ng/ml Established as Standard by the U.S. Department of Health and Human
Services, World Health Organization and
SAMHSA (NIDA).
|
|
INTENDED USE
|
For a comprehensive
discussion on drug of abuse testing including typical detection time periods
see the DRUG
TESTING FAQ |
The QuickScreen™ One-Step Rapid MDMA (Ecstasy) Test is a rapid, qualitative, competitive binding immunoassay for the
specific detection of Methylenedioxymethamphetamine
(MDMA) metabolites in urine. The test provides a fast (3
minute) confirmation of the presence of MDMA in the subject sample at a minimum cutoff sensitivity level of 500
ng/ml MDMA. Note: it is recommended that any positive test be confirmed using quantitative methods by a qualified healthcare professional.
Note: This assay provides only a preliminary analytical test result. A more specific alternative chemical method such as high-pressure liquid chromatography (HPLC) or Gas chromatography/mass spectrometry (GC/MS) must be used in order to obtain a confirmed analytical result. For test situations requiring laboratory confirmation by such methods please refer to the
QuickScreen Pro At Home
Test Kit. Clinical consideration and professional judgment should be applied to all test results, particularly when preliminary positive results are indicated.
SUMMARY AND EXPLANATION OF THE TEST
Methylenedioxymethamphetamine (Ecstasy) is a designer drug first synthesized in
1913 by a German drug company for the treatment of obesity. Those who take the
drug frequently report adverse effects, such as increased muscle tension and
sweating. MDMA is not clearly a stimulant, although it has, in common with
amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA
does produce some perceptual changes in the form of increased sensitivity to
light, difficulty in focusing, and blurred vision in some users. Its mechanism
of action is thought to be via release of the neurotransmitter serotonin. MDMA
may also release dopamine, although the general opinion is that this is a
secondary effect of the drug. The most pervasive effect of MDMA, occurring in
almost all people who have taken a reasonable dose of the drug, is to produce a
clenching of the jaws. The MDMA Ecstasy Test yields a
positive result when Methylenedioxymethamphetamine in urine exceeds 500ng/ml
which is the NIDA standard.
The excretion half-life of MDMA metabolized in urine,
estimated by different techniques, ranges from two to three days. The QuickScreen™ One-Step
Ecstasy Test employs a unique combination of
monoclonal antibodies to selectively identify MDMA
metabolites in urine with a high degree of
sensitivity. The test device is a rapid, visually read screening test that does not require instrumentation and provides a fast indication of recent
Ecstasy consumption.
For comprehensive information on drug
testing including typical half-life or drug detection periods see the
Drug Testing FAQ.
PRINCIPLE
 The QuickScreen™ One-Step Rapid
MDMA Test technology incorporates a chromatographic
absorbent device in which the drug or drug metabolites in the sample compete
with a MDMA derivative immobilized on a porous
membrane for limited antibody sites. This is the preferred scientific method for
qualitative assay. In the assay procedure, urine mixes with labeled antibody-dye
conjugate and migrates through test device. When MDMA levels are below 500
ng/ml (the detection cutoff sensitivity of the test) unbound antibody-dye
conjugate binds to immobilized antigen conjugate in the Test Zone ("T"),
producing a pink-rose colored band that indicates a negative result. Conversely,
when MDMA levels are above the detection limit, antibody-dye conjugate binds to the free drug, forming an antigen-antibody-dye complex. The complex competes with immobilized antigen conjugate in the Test Zone, preventing the development of a pink-rose colored band. Regardless of the test result, a color band is produced in the Control Zone ("C") by a non-specific sandwich dye conjugate reaction. This band serves as a built-in quality control by demonstrating antibody recognition, verifying that the reagents are chemically active, and confirming that the test was performed correctly.
MATERIALS PROVIDED:
QuickScreen™ One-Step MDMA test device and dropper pipette individually sealed in foil pouch with complete
instructions.
ASSAY
PROCEDURE
-
Collect a urine sample from test subject using a suitable clean container preferably glass.
-
Refrigerated specimens or other materials should be equilibrated to room temperature before testing.
-
Open the foil pouch at the notch, remove the test device, and label the device with specimen ID.
-
Holding the dropper vertically as shown, add
4 drops of urine into the sample well "S"
waiting 5 seconds between drops.
-
Observe migration, or lateral flow of the sample across the entire test
panel. Add additional sample drops if migration is not complete.
-
Positive results may be observed as soon as
3 minutes, depending on the concentration of the
MDMA in the tested specimen. To confirm negative results, a complete
reaction time of 8 minutes is required. Do not interpret results after
10 minutes.
INTERPRETATION OF TEST RESULTS:
|
|
|
|
|
Negative
|
Positive |
Invalid |
|
The
development of two lines, a control line and a test line, no matter how
faint, in the test result window indicates a negative test screen for
the targeted drug or drug metabolite.
|
The
development of only one line, the control line, in the test result
window indicates a positive test screen for the targeted drug or drug
metabolite
|
The
absence of a control line in the test result window indicates an invalid
test result regardless of the presence of a test line in the test result
window.
|
Positive: One (1) pink-rose band appears in the control zone and no band appears
in the test zone. A positive result indicates MDMA level is 500 ng/ml or higher in the test urine sample.
Negative: One band appears in the test zone and one band appears in the control
zone. A negative result indicates that MDMA level is below the detection sensitivity of 500 ng/ml. IMPORTANT: any line, no matter how faint, appearing in the test area confirms a negative test.
Invalid: If there are no distinct color bands visible in both the test zone and the control zone or if there is a visible band in the test zone but not in the control zone, then the test is invalid. In this instance, re-testing of the specimen is recommended.
TEST AVAILABILITY
The QuickScreen™ One-Step Rapid MDMA Test is now available to professionals
and individuals concerned with MDMA consumption or abuse. The test is
one-step, fast, self-contained, individually packaged and can be performed any
time the targeted drug use or abuse is suspected. The tests come in order units
of five (5) individual tests at a cost per single diagnosis/screen of $4.00 for
the minimum order unit. For testing situations where sample adulteration is
suspect, a Rapid Urine Adulteration test is
available.
| Test Description/Type |
Quantity |
Cost |
|
|
QuickScreen
MDMA (Ecstasy) Cassette Test |
Five
(5) Tests |
$19.90 |
 |
| |
Fifteen
(15) Tests |
$45.00 |
|
| |
Thirty
(30) Tests |
$75.00 |
|
| |
One Hundred
(100) Tests |
$190.00 |
|
|
|
Two Hundred
Fifty
(250) Tests |
$375.00 |
|
|
*If the
order buttons are absent or inoperable, please use the
pricing overview page to order. |
|
